Grant McArthur

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. doi request reprint Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia Electronic address
    Lancet Oncol 15:323-32. 2014
  2. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
  3. doi request reprint Targeting oncogenic drivers and the immune system in melanoma
    Grant A McArthur
    Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Clin Oncol 31:499-506. 2013
  4. doi request reprint The granulocyte-colony stimulating factor receptor (G-CSFR) interacts with retinoic acid receptors (RARs) in the regulation of myeloid differentiation
    Lynette C Y Chee
    Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Leukoc Biol 93:235-43. 2013
  5. doi request reprint Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
    Grant A McArthur
    Peter MacCallum Cancer Centre, Melbourne, VIC 8006, Australia
    J Clin Oncol 30:1628-34. 2012
  6. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
  7. doi request reprint Splicing the way to leukemia with KIT
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 49:1431-2. 2008
  8. ncbi request reprint Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Curr Opin Oncol 18:341-6. 2006
  9. ncbi request reprint Dermatofibrosarcoma protuberans: recent clinical progress
    Grant McArthur
    Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia, 3002
    Ann Surg Oncol 14:2876-86. 2007
  10. ncbi request reprint Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Clin Oncol 23:866-73. 2005

Detail Information

Publications51

  1. doi request reprint Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia Electronic address
    Lancet Oncol 15:323-32. 2014
    ..We present an extended follow-up analysis of the total population and in the BRAF(V600E) and BRAF(V600K) mutation subgroups...
  2. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
    ....
  3. doi request reprint Targeting oncogenic drivers and the immune system in melanoma
    Grant A McArthur
    Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Clin Oncol 31:499-506. 2013
    ....
  4. doi request reprint The granulocyte-colony stimulating factor receptor (G-CSFR) interacts with retinoic acid receptors (RARs) in the regulation of myeloid differentiation
    Lynette C Y Chee
    Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Leukoc Biol 93:235-43. 2013
    ..However, with the loss of G-CSFR, this expansion in granulopoiesis was attenuated, supporting the hypothesis that G-CSFR signaling interacts with RARs in the regulation of myeloid differentiation...
  5. doi request reprint Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
    Grant A McArthur
    Peter MacCallum Cancer Centre, Melbourne, VIC 8006, Australia
    J Clin Oncol 30:1628-34. 2012
    ..We aimed to determine the metabolic response rate to vemurafenib in patients with advanced BRAF-mutant melanoma...
  6. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
    ..CONCLUSION: These data demonstrate that activation of GF signaling pathways, independent of HER2 over-expression, could be contributing to the poor prognosis of the luminal-B ER+ BC subtype...
  7. doi request reprint Splicing the way to leukemia with KIT
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 49:1431-2. 2008
  8. ncbi request reprint Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Curr Opin Oncol 18:341-6. 2006
    ..This review will examine recent data confirming the central role of surgery in managing this disease and new findings for the application of molecularly targeted therapy in patients with unresectable disease...
  9. ncbi request reprint Dermatofibrosarcoma protuberans: recent clinical progress
    Grant McArthur
    Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia, 3002
    Ann Surg Oncol 14:2876-86. 2007
    ....
  10. ncbi request reprint Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Clin Oncol 23:866-73. 2005
    ..The purpose of this study was to evaluate molecular, cytogenetic, and kinase activation profiles in a series of DFSPs and to determine whether these biologic parameters are correlated with the clinical responses of DFSP to imatinib...
  11. ncbi request reprint Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Natl Compr Canc Netw 5:557-62. 2007
    ....
  12. ncbi request reprint Molecularly targeted treatment for dermatofibrosarcoma protuberans
    Grant McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Australia
    Semin Oncol 31:30-6. 2004
    ..Imatinib may provide an alternative for the treatment of unresectable or partially resectable tumors, thereby possibly improving the effectiveness of surgery...
  13. ncbi request reprint Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas
    Wendy Liu
    Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia
    Arch Dermatol 142:1551-8. 2006
    ..To investigate the spectrum of growth rates in melanomas and to identify clinical associations of rapidly growing melanomas...
  14. ncbi request reprint Sensitive detection of KIT D816V in patients with mastocytosis
    Angela Tan
    Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Clin Chem 52:2250-7. 2006
    ....
  15. ncbi request reprint The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas
    Kenneth K Khamly
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Expert Rev Mol Diagn 8:105-19. 2008
    ..This article will discuss the above issues, using the setting of sarcomas as an example...
  16. ncbi request reprint An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development
    Carleen Cullinane
    Sir Donald and Lady Trescowthick Laboratories and Center for Molecular Imaging, Peter MacCallum Cancer Center, Melbourn, Victoria, Australia
    Cancer Res 65:9633-6. 2005
    ..Further, the FDC-P1 model represents a very useful paradigm for molecularly targeted drug development...
  17. pmc Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial
    Danny Rischin
    Department of Medical Oncology, Peter MacCallum Cancer Centre, A Beckett St, Locked Bag No 1, Melbourne 8006, Australia
    J Clin Oncol 28:4142-8. 2010
    ..To determine the prognostic importance of p16 and human papillomavirus (HPV) in patients with oropharyngeal cancer treated on a phase III concurrent chemoradiotherapy trial...
  18. doi request reprint Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model
    Carleen Cullinane
    Translational Research Laboratory, Research Division, East Melbourne, Victoria, Australia
    Mol Cancer Ther 9:1461-8. 2010
    ..These findings show the in vivo activity of nilotinib in the treatment of tumors bearing V560G-KIT but not D816V-KIT and the utility of FDG-PET imaging to assess tumor response to this agent...
  19. pmc Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma
    David M Thomas
    Ian Potter Foundation Centre for Cancer Genomics and Predictive Medicine, and Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Center, Victoria, Melbourne, Australia
    J Cell Biol 167:925-34. 2004
    ..Physiologic coupling of osteoblast differentiation to cell cycle withdrawal is mediated through runx2 and p27KIP1, and these processes are disrupted in osteosarcoma...
  20. ncbi request reprint Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study
    David E Gyorki
    Peter MacCallum Cancer Centre, Skin and Melanoma Service, St Andrew s Place, East Melbourne, Victoria 3002, Australia
    Melanoma Res 14:223-30. 2004
    ..We conclude that concurrent use of adjuvant radiotherapy and IFNalpha2b may enhance radiation-induced toxicity. However, overall we found concurrent radiation and IFNalpha2b could be safely delivered with appropriate clinical monitoring...
  21. doi request reprint Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer
    Despina Handolias
    Peter MacCallum Cancer Centre, Department of Haematology and Medical Oncology, Locked Bag 1, A Beckett Street, Victoria 8006, Australia
    Future Oncol 4:211-7. 2008
    ..New insight into this fundamental biological mechanism sets the scene for the further development of molecular-targeted therapeutic options for cancer...
  22. doi request reprint Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure
    Despina Handolias
    Research Division Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia
    Pigment Cell Melanoma Res 23:210-5. 2010
    ..In the remaining cohort, 43% had chronically sun damaged skin. This report confirms that within an Australian population, KIT mutations are infrequent in cutaneous melanomas associated with both intermittent and chronic sun exposed skin...
  23. doi request reprint Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma
    Sarah Jane Dawson
    Department of Haematology and Medical Oncology, The University of Melbourne, Melbourne, Victoria, Australia
    Anticancer Drugs 19:547-52. 2008
    ..Sunitinib seems to be a promising agent in the treatment of thyroid cancers and this requires validation in future clinical trials...
  24. doi request reprint Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
    Bianca Devitt
    Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Pigment Cell Melanoma Res 24:666-72. 2011
    ..96; P = 0.04] but not BRAF(V600E) mutations (HR 1.73; P = 0.23). NRAS mutations were associated with thicker tumors and higher rates of mitosis when compared to BRAF(V600E) and WT melanoma and independently of this, with shorter MSS...
  25. ncbi request reprint Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers
    Andrew J Deans
    Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer Res 66:8219-26. 2006
    ..Moreover, inhibitors of CDKs may be useful therapeutics in cancers with defects in DNA repair, such as mutations in the familial breast cancer gene BRCA1...
  26. ncbi request reprint EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor
    Benjamin Solomon
    Research Division, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 55:713-23. 2003
    ....
  27. ncbi request reprint Identification of the molecular requirements for an RAR alpha-mediated cell cycle arrest during granulocytic differentiation
    Carl R Walkley
    Division of Research, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, 3002, Australia
    Blood 103:1286-95. 2004
    ..Moreover, these data demonstrate selectivity among the RARs for cell cycle arrest pathways and provide a direct mechanism to link differentiation induction and regulation of the Myc antagonist Mad1...
  28. doi request reprint Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial
    Ian D Davis
    Ludwig Oncology Unit, Austin Health, Melbourne, Victoria, Australia
    Clin Cancer Res 15:2123-9. 2009
    ..We report final clinical and biological results of a phase II study of recombinant human IL-21 (rIL-21) in patients with metastatic melanoma...
  29. doi request reprint Review: mucosal melanoma of the head and neck
    Haim Gavriel
    Melanoma and Skin Service and Head and Neck Service, Division of Surgical Oncology, Department of Surgical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia
    Melanoma Res 21:257-66. 2011
    ..We strongly recommend further evaluation of the role of chemotherapy and immunotherapy to decrease the rates of distant metastasis and improve survival...
  30. ncbi request reprint Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma
    Wendy Liu
    Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    J Invest Dermatol 127:900-5. 2007
    ..Although implicated in the control of the cell cycle, the BRAF(T1799A) mutation is associated with a lower rate of tumor proliferation...
  31. ncbi request reprint Cell division and hematopoietic stem cells: not always exhausting
    Carl R Walkley
    Research Division, Peter MacCallum Cancer Centre, Victoria, Australia
    Cell Cycle 4:893-6. 2005
    ..One of the emerging themes of these studies is that of the importance of cell cycle regulators in the maintenance of HSCs...
  32. ncbi request reprint Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells
    Carl R Walkley
    Research Division, Peter MacCallum Cancer Centre, Victoria 3002, Australia
    Nat Cell Biol 7:172-8. 2005
    ..Together these data demonstrate that the MYC-antagonist MAD1 and cyclin-dependent kinase inhibitor p27(Kip1) cooperate to regulate the self-renewal and differentiation of HSCs in a context-dependent manner...
  33. pmc PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
    Proc Natl Acad Sci U S A 107:10208-13. 2010
    ..In ER+ BC cell lines, PIK3CA mutations were also associated with sensitivity to tamoxifen. These findings could have important implications for the treatment of PIK3CA-mutant BCs and the development of PI3K/mTOR inhibitors...
  34. pmc MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation
    Gretchen Poortinga
    Division of Research, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia
    EMBO J 23:3325-35. 2004
    ....
  35. pmc mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF
    Katherine M Hannan
    Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, USA
    Mol Cell Biol 23:8862-77. 2003
    ..Thus, mTOR plays a critical role in the regulation of ribosome biogenesis via a mechanism that requires S6K1 activation and phosphorylation of UBF...
  36. pmc UBF levels determine the number of active ribosomal RNA genes in mammals
    Elaine Sanij
    Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    J Cell Biol 183:1259-74. 2008
    ..We also show that the active rRNA gene pool is not static but decreases during differentiation, correlating with diminished UBF expression. Thus, UBF1 levels regulate active rRNA gene chromatin during growth and differentiation...
  37. doi request reprint Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation
    Meaghan Wall
    Division of Research, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Blood 112:2305-17. 2008
    ..These findings suggest that mTORC1 could be targeted to promote terminal differentiation in myeloid malignancies characterized by dysregulated expression of c-MYC...
  38. ncbi request reprint An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma
    Ian D Davis
    Austin Health, Melbourne, Victoria, Australia
    Clin Cancer Res 13:3630-6. 2007
    ....
  39. ncbi request reprint Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033
    Donna S Dorow
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Eur J Nucl Med Mol Imaging 33:441-52. 2006
    ..This study was designed as "proof of concept" for a drug development model utilising multi-tracer serial small animal PET imaging to characterise tumour responses to molecularly targeted therapy...
  40. doi request reprint Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma
    Theo Nicholaou
    Ludwig Institute for Cancer Research, Austin Health, Peter MacCallum Cancer Centre, CSL Limited, Melbourne, Victoria, Australia
    Clin Cancer Res 15:2166-73. 2009
    ..This study examines the clinical and immunologic efficacy of the same vaccine in patients with advanced metastatic melanoma...
  41. pmc A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency
    Carl R Walkley
    Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, 3002, Australia
    Cell 129:1097-110. 2007
    ..These data show that loss of RARgamma results in a nonhematopoietic cell-intrinsic MPS, revealing the capability of the microenvironment to be the sole cause of hematopoietic disorders...
  42. ncbi request reprint Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary gland
    Andrew J Deans
    Molecular Oncology Laboratory, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne 3002, Australia
    Oncogene 23:6136-45. 2004
    ..We hypothesize that disruption of BRCA1 induces an increase in p27 that inhibits proliferation. Accordingly, reduction in p27 expression leads to enhancement of cellular proliferation in the absence of BRCA1...
  43. ncbi request reprint Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma
    Malcolm Ranson
    Department of Medical Oncology, University of Manchester, United Kingdom
    J Clin Oncol 25:2540-5. 2007
    ....
  44. ncbi request reprint Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders
    Marianna David
    Department of Haematology, University of Pecs, Pecs, Hungary
    Blood 109:61-4. 2007
    ..Our data show that durable hematologic and cytogenetic responses are achieved with imatinib in patients with PDGFRB fusion-positive, BCR-ABL-negative CMPDs...
  45. ncbi request reprint BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage
    Megan Fabbro
    Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    J Biol Chem 279:31251-8. 2004
    ..These findings suggest that BRCA1-BARD1 complexes act as an adaptor to mediate ATM/ATR-directed phosphorylation of p53, influencing G(1)/S cell cycle progression after DNA damage...
  46. ncbi request reprint Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
    Michael C Heinrich
    Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR, USA
    J Clin Oncol 24:1195-203. 2006
    ..To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent...
  47. pmc IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma
    Klaus Stensgaard Frederiksen
    Novo Nordisk A S, Novo Nordisk Park, Maalov, Denmark
    Cancer Immunol Immunother 57:1439-49. 2008
    ..Here we report the effects of systemic IL-21 therapy on the immune system in two phase 1 trials with this novel cytokine...
  48. pmc MAD1 and p27(KIP1) cooperate to promote terminal differentiation of granulocytes and to inhibit Myc expression and cyclin E-CDK2 activity
    Grant A McArthur
    Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Mol Cell Biol 22:3014-23. 2002
    ..We conclude that Mad1 and p27(KIP1) operate, at least in part, by distinct mechanisms to downregulate CDK2 activity and Myc expression in order to promote cell cycle exit during differentiation...
  49. doi request reprint Correlation of subjective self-reported melanoma growth rate with objective tumor proliferation markers
    Wenyuan Liu
    Arch Dermatol 144:555-6. 2008
  50. ncbi request reprint Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome
    Tara Seshadri
    N Engl J Med 351:2134-5. 2004
  51. ncbi request reprint Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging
    Benjamin Solomon
    Research Division, Peter MacCallum Cancer Institute, Melbourne, Australia
    Mol Cancer Ther 4:1417-22. 2005
    ..A strong correlation was observed between pimonidazole binding and FAZA uptake. Together, these findings show that gefitinib reduces intratumoral hypoxia...